{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-008894","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.677025+00:00","generated_at":"2026-06-06T13:59:32.523201+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gain Therapeutics CEO provides operational update; Phase 1 trial advancing, cash runway into 2025","bullets":["Phase 1 SAD/MAD trial of GT-02287 underway; MAD cohort expected to start Q1 2024, completion by mid-2024.","$10.1M gross proceeds from Nov 2023 CMPO/PIPE financing; cash runway into 2025 to fund biomarker proof-of-concept.","Computational platform renamed Magellan, now integrates AI/ML and screens 50B+ chemical compounds.","CTO Dr. Xavi Barril leaving; company searching for Chief Medical Officer for clinical development.","Anticipated milestones: MAD completion, Parkinson's patient cohort Q3 2024, biomarker data late 2024/early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-008894","json":"https://secwatch.observer/filing/0001104659-24-008894.json","markdown":"https://secwatch.observer/filing/0001104659-24-008894.md","text":"https://secwatch.observer/filing/0001104659-24-008894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924008894/0001104659-24-008894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924008894/tm244785d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T13:59:32.523201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}